skip to primary navigationskip to content
 

Professor David Rowitch

107-Rowitch-2017Professor David Rowitch

Glial cells and response to injury

Email: dhr25@cam.ac.uk

Laboratory: Cambridge Stem Cell Institute, Clifford Allbutt Building, Cambridge Biomedical Campus.

Departmental Affiliation: Paediatrics

Biography

David Rowitch, MD PhD ScD is Professor and Head of Paediatrics at the University of Cambridge, and he holds a joint appointment at UCSF (Pediatrics and Neurological Surgery). He is a neonatologist and neuroscientist whose laboratory investigates genetic factors that determine development and diversity of glial cells of the brain and the response to injury. He has applied these principles to better understand white matter injury in premature infants, brain cancer and leukodystrophy. Rowitch lead the first human clinical trial of direct neural stem cell transplantation focused on the rare and fatal leukodystrophy, Pelizaeus-Merzbacher Disease (PMD).

His work in the field of neurobiology has earned him numerous awards. He became a Howard Hughes Medical Institute Investigator in 2008 and Professor of Paediatrics at Cambridge University and Wellcome Trust Senior Investigator in 2016. His interest in precision medicine focuses on applications of genomic technologies to diagnose and better understand the biological basis and rational treatment of rare neurological disorders.

Funding

 Wellcome Trust, Action Medical Research

 

Rowitch Research 2017

Image from my lab taken by Vivi Heine in 2008 shows a collection neural stem cells stained with nestin (green), and Olig2 (red), a marker of glial progenitors. Such cell collections can "self-organize" to generate specialized cell progeny without external instructions

 

Research

David Rowitch, MD PhD ScD is Professor and Head of Paediatrics at University of Cambridge. He holds a joint appointment at UCSF (Pediatrics and Neurological Surgery). He is a neonatologist and neuroscientist whose laboratory investigates genetic factors that determine development and diversity of glial cells of the brain and the response to injury. He has applied these principles to better understand white matter injury in premature infants, brain cancer and leukodystrophy. Rowitch leads the first human clinical trial of direct neural stem cell transplantation focused on the rare and fatal leukodystrophy, Pelizaeus-Merzbacher Disease (PMD). His work in the field of neurobiology has earned him numerous awards. He became a Howard Hughes Medical Institute Investigator in 2008 and Professor of Paediatrics at Cambridge University and Wellcome Trust Senior Investigator in 2016. His interest in precision medicine focuses on applications of genomic technologies to diagnose and better understand the biological basis and rational treatment of rare neurological disorders. 

 

Rowitch Group 2017

Group Members

Staffan Holmqvist, Srikirti Kodali, John Stockley  

 

Plain English 

 

Key Publications